Is 10x Genomics on the NASDAQ?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG." Who are 10x Genomics' major shareholders? 10x Genomics' stock is owned by a number of institutional and retail investors.

What is the analyst consensus target price for 10x Genomics?

The analyst consensus target price for shares in 10X Genomics is $192.38 . That is 36.14% above the last closing price of $141.31. Analysts covering 10X Genomics currently have a consensus Earnings Per Share (EPS) forecast of -$0.44 for the next financial year.

What is 10x Genomics' Xenium?

At launch, Xenium is expected to offer single-molecule RNA analysis at subcellular resolution and be compatible with both fresh frozen and FFPE tissues. In addition, 10x Genomics is developing Xenium to have the highest throughput of any instrument in its class.

Does Amalgamated Bank own 10x Genomics (TXG)?

Amalgamated Bank’s holdings in 10x Genomics were worth $1,487,000 as of its most recent SEC filing. A number of other institutional investors have also bought and sold shares of TXG. D1 Capital Partners L.P. purchased a new stake in shares of 10x Genomics during the 4th quarter valued at approximately $239,081,000.